GlassScriptPhysician profile
David J Klashman
NPI 1265451777
$10,800.67
in general payments reported to CMS, 2019-2025
27 companies · $820 in 2025
The $820 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,946 · 2020: $1,763 · 2021: $2,276 · 2022: $1,525 · 2023: $1,474 · 2024: $996 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,274 · Education: $15.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,274.00 |
| Education | $15.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,685.28 | 2019-2025 | |
| Janssen Biotech, INC. | $1,452.12 | 2019-2025 | Tremfya |
| Amgen INC. | $1,356.64 | 2019-2024 | Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $1,241.00 | 2019-2025 | |
| Pfizer INC. | $900.01 | 2019-2023 | |
| Lilly USA, LLC | $350.95 | 2019-2023 | Taltz |
| Astrazeneca Pharmaceuticals LP | $327.35 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $304.55 | 2019-2023 | Orencia |
| Ucb, INC. | $303.69 | 2019-2023 | Cimzia |
| Celgene Corporation | $295.20 | 2019 | |
| Fresenius Kabi USA, LLC | $265.65 | 2023-2025 | |
| Genzyme Corporation | $254.69 | 2019-2021 | |
| Glaxosmithkline, LLC. | $251.54 | 2019-2023 | Benlysta |
| Horizon Therapeutics Plc | $225.57 | 2019-2021 | |
| Organon LLC | $87.46 | 2021-2024 | Hadlima |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $85.20 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $82.62 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $57.01 | 2023 | Acthar |
| Radius Health, INC. | $52.94 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $44.51 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $37.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.46 | 2021 | |
| Ani Pharmaceuticals, INC. | $30.11 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $27.67 | 2019 | |
| Genentech USA, INC. | $16.97 | 2019 | |
| Celltrion USA INC. | $15.98 | 2023 | Yuflyma |
| Hikma Pharmaceuticals USA | $14.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Klashman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.